Income statement, balance sheet and cash flow statement for the last 3 fiscal years, taken from the XBRL data Telix Pharmaceuticals Ltd files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2023
FY2025
FY2025
Revenue
333
517
804
Cost of revenue
123
180
377
Gross profit
210
336
426
Research and development
85.3
128
171
Operating income
11
55.2
29.8
Interest expense
9.09
24.4
40.9
Interest income
0.67
7.18
5.83
Pre-tax income
2.59
37.9
-5.27
Income tax
-1.61
4.23
1.86
Net income
4.21
33.7
-7.13
EBITDA
15.5
60
51.3
EPS, basic
0.01
0.10
-0.02
EPS, diluted
0.01
0.10
-0.02
Balance sheet
FY2023
FY2025
FY2025
Cash and equivalents
84.3
440
142
Receivables
44
86.9
129
Inventory
12.7
23.6
37.1
Total current assets
159
570
330
Property, plant and equipment
15.8
27.8
58.7
Lease right-of-use assets
5.01
5.81
57
Goodwill
66.6
199
Intangible assets
258
593
Total assets
277
940
1,164
Accounts payable
54.3
86.8
150
Short-term debt
0.66
11.8
13.1
Total current liabilities
111
205
232
Lease liabilities
5.25
5.04
56.5
Total liabilities
175
587
749
Total debt
354
405
Retained earnings
-187
-153
-155
Total equity
103
353
415
Total liabilities and equity
277
940
1,164
Cash flow statement
FY2023
FY2025
FY2025
Net income
4.21
33.7
-7.13
Depreciation and amortization
4.49
4.85
21.5
Cash from operations
14.3
27.5
-17.3
Capital expenditures
-6.31
-9.12
-25.7
Cash from investing
-16.8
-86.7
-286
Debt issued
4.19
428
0.53
Debt repaid
0
-0.75
-0.82
Cash from financing
7.09
417
-3.72
Exchange rate effect
0.99
-1.89
8.8
Free cash flow
7.97
18.4
-43
Interest paid
0.39
3.09
13.7
Income taxes paid
6.86
2.03
21.3
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. Valuation uses the share price of $11.45 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
53.1%
Gross profit / revenue.
Operating margin
3.7%
Operating income / revenue.
EBITDA margin
6.4%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-0.7%
Pre-tax income / revenue.
Net margin
-0.9%
Net income / revenue.
FCF margin
-5.3%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-2.2%
Cash from operations / revenue.
Return on assets (ROA)
-0.7%
Net income / average total assets.
R&D / revenue
21.3%
Research and development expense / revenue.
Capex / revenue
3.2%
Capital expenditures / revenue.
D&A / revenue
2.7%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
55.6%
Revenue vs the same period a year earlier. Only from a positive base.
Gross profit growth, 1y
26.9%
Gross profit vs the same period a year earlier. Only from a positive base.
Operating income growth, 1y
-46.0%
Operating income vs the same period a year earlier. Only from a positive base.
EBITDA growth, 1y
-14.6%
EBITDA vs the same period a year earlier. Only from a positive base.
Net income growth, 1y
-121.2%
Net income vs the same period a year earlier. Only from a positive base.
EPS growth, 1y
-121.6%
EPS vs the same period a year earlier. Only from a positive base.
Operating cash flow growth, 1y
-162.9%
Operating cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow growth, 1y
-334.0%
Free cash flow vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
23.8%
Total assets vs the same period a year earlier. Only from a positive base.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.43x
Current assets / current liabilities.
Quick ratio
1.17x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.61x
(Cash + short-term investments) / current liabilities.
Debt / assets
34.8%
Total debt / total assets.
Liabilities / assets
64.3%
Total liabilities / total assets.
Net debt
$263.2M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net debt / EBITDA
5.13x
Net debt / EBITDA (twelve months), when EBITDA is positive.
Interest coverage
0.73x
Operating income / interest expense.
Working capital
$98.7M
Current assets - current liabilities.
Goodwill and intangibles / assets
68.0%
(Goodwill + intangible assets) / total assets.
Efficiency
Metric
Value
How it is calculated
Asset turnover
0.76x
Revenue / average total assets.
Fixed asset turnover
18.6x
Revenue / average property, plant and equipment.
Inventory turnover
12.4x
Cost of revenue / average inventory.
Days inventory
29 days
365 x average inventory / cost of revenue.
Receivables turnover
7.44x
Revenue / average receivables.
Days sales outstanding
49 days
365 x average receivables / revenue.
Days payables
115 days
365 x average accounts payable / cost of revenue.
Cash conversion cycle
-36 days
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$0.02
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$0.02
Net income per basic share, as reported (split-adjusted).
Valuation
Metric
Value
How it is calculated
Market cap
$3.88B
Share price x shares outstanding.
Enterprise value
$4.14B
Market cap + total debt - cash - short-term investments.
P/S
4.83x
Market cap / revenue.
EV/Sales
5.15x
Enterprise value / revenue.
EV/EBIT
139x
Enterprise value / operating income, when both are positive.
EV/EBITDA
80.8x
Enterprise value / EBITDA, when both are positive.
FCF yield
-1.1%
Free cash flow / market cap.
Earnings yield
-0.2%
Net income / market cap (the inverse of P/E).
What was Telix Pharmaceuticals Ltd's revenue in fiscal 2025?
Telix Pharmaceuticals Ltd reported revenue of $803.8M for fiscal 2025, 55.6% higher than the year before.
Was Telix Pharmaceuticals Ltd profitable in fiscal 2025?
No. It reported a net loss of $7.1M.
How much free cash flow did Telix Pharmaceuticals Ltd generate in fiscal 2025?
Cash from operations of $17.3M minus capital expenditures of $25.7M left free cash flow of -$43.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.